Willkie represents biopharmaceutical company Clovis Oncology, Inc. in its underwritten public offering of 3,525,641 shares of its common stock.
On July 8, Willkie client Clovis Oncology, Inc. announced the pricing of an underwritten public offering of 3,525,641 shares of its common stock at $78.00 per share, before underwriting discounts and commissions. In addition, the underwriters have a 30-day option to purchase up to an additional 528,846 shares of common stock from Clovis Oncology. J. P. Morgan Securities LLC is acting as lead book-running manager and representative of the underwriters for the offering. Credit Suisse Securities (USA) LLC is also acting as a joint book-runner, and Stifel and Mizuho Securities are acting as co-managers for the offering. The offering is expected to close on July 14.
Based in Boulder, CO, Clovis Oncology is a biopharmaceutical company focused on acquiring, developing and commercializing innovative anti-cancer agents in the U.S., Europe and additional international markets. Willkie previously represented Clovis Oncology in its IPO, several subsequent equity offerings and a 144A offering of convertible senior notes. Willkie has also represented Clovis Oncology in numerous acquisitions and licensing deals of products and businesses.
The current transaction was handled by partner Thomas Mark and associates Michael Brandt, Kathleen O'Donnell and Michal Flombaum.